High Blood PressurePhase 1NCT00960245
Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions
A Phase 1 study testing Nadolol (1 x 80 mg) Tablets (Invamed, Inc) and Corgard (1 x 80 mg) Tablets (Bristol Laboratories) in people with High Blood Pressure and Migraine Headaches, run by Sandoz.
Trial summary
The purpose of this study is to demonstrate the relative bioavailability of Nadolol (1 x 80 mg) tablets under fasting conditions. Read more about this study
- Who is it for?
- Ages 18 to 40 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- High Blood Pressure, Migraine Headaches, Chest Pain
- What is being tested?
- Nadolol (1 x 80 mg) Tablets (Invamed, Inc) and Corgard (1 x 80 mg) Tablets (Bristol Laboratories)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 34 participants
- Where
- No sites listed yet
- Study dates
- Jul 1994to Jul 1994
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.
Who cannot join
- Positive test results for HIV or hepatitis B or C.
- Treatment for drug or alcohol dependence.
About this study
Official title: A Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions.
The purpose of this study is to demonstrate the relative bioavailability of Nadolol (1 x 80 mg) tablets under fasting conditions.
- Conditions
- High Blood Pressure, Migraine Headaches, Chest Pain
- Being tested
- Nadolol (1 x 80 mg) Tablets (Invamed, Inc), Corgard (1 x 80 mg) Tablets (Bristol Laboratories)
- Medical subject headings
- Hypertension, Migraine Disorders, Chest Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nadolol (1 x 80 mg) Tablets (Invamed, Inc)Drug
Corgard (1 x 80 mg) Tablets (Bristol Laboratories)Drug
| Study group | Role | What they receive |
|---|---|---|
| 1 | Experimental | Nadolol (1 x 80 mg) Tablets (Invamed, Inc) Receives: Drug: Nadolol (1 x 80 mg) Tablets (Invamed, Inc) |
| 2 | Active comparator | Corgard (1 x 80 mg) Tablets (Bristol Laboratories) Receives: Drug: Corgard (1 x 80 mg) Tablets (Bristol Laboratories) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Bioequivalence based on AUC and Cmax
Measured: 21 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Aug 2009 (estimated)
- Study startJul 1994
- Primary completionJul 1994
- Study completionJul 1994
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for High Blood PressureStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 34 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sandoz
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- Terry L. Wolff, D.O., Principal investigator, MeritCare Broadway Health Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00960245
- Sponsor's protocol ID
- PRACS P94-102
- Status last verified
- Aug 2009
- First submitted
- 13 Aug 2009
- Last updated
- 28 Mar 2017
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Mar 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions.
- ClinicalTrials.gov ID
- NCT00960245
- Acronym / sponsor ID
- PRACS P94-102
- Conditions
- High Blood Pressure, Migraine Headaches, Chest Pain
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 34 participants (actual)
- Lead sponsor
- SandozIndustry (pharma, biotech, devices)
- Study start
- Jul 1994
- Primary completion
- Jul 1994 (actual)
- Study completion
- Jul 1994 (actual)
- First posted
- 17 Aug 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to demonstrate the relative bioavailability of Nadolol (1 x 80 mg) tablets under fasting conditions.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 1 | Experimental | Drug: Nadolol (1 x 80 mg) Tablets (Invamed, Inc)Nadolol (1 x 80 mg) Tablets (Invamed, Inc) |
| 2 | Active comparator | Drug: Corgard (1 x 80 mg) Tablets (Bristol Laboratories)Corgard (1 x 80 mg) Tablets (Bristol Laboratories) |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.
Key exclusion criteria (2 listed)
- Positive test results for HIV or hepatitis B or C.
- Treatment for drug or alcohol dependence.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nadolol (1 x 80 mg) Tablets (Invamed, Inc) | Drug | 1 |
| Corgard (1 x 80 mg) Tablets (Bristol Laboratories) | Drug | 2 |
Primary outcome
Bioequivalence based on AUC and Cmax
Time frame: 21 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Mar 2017.
Related trials for High Blood Pressure
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Enrolling by invitation
Testing Implementation Strategies to Support Clinic Fidelity to an Outpatient Hypertension Bundle
Pregnancy Related, Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Terry L. Wolff, D.O. principal investigator
MeritCare Broadway Health Center
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Nadolol (1 x 80 mg) Tablets (Invamed, Inc) and Corgard (1 x 80 mg) Tablets (Bristol Laboratories) in people with High Blood Pressure and Migraine Headaches, run by Sandoz.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Mar 2017. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Bioequivalence based on AUC and Cmax (time frame: 21 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Mar 2017.